Kimberly Kenne, MD
Urogynecology and Reconstructive Pelvic Surgery · Iowa City, IANPI 1407168305
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Boston Scientific at 58.6% of the total.
Across 14 payments — averaging $75.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$618
- Medtronic$174
- AbbVie$101
- Valencia Technologies Corporation$62
- Caldera Medical, Inc$53
- Applied Medical Resources Corporation$48
What the payments were for
- Food & beverage$1,00295%
- Gifts$535%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 8 | $618 |
| Medtronic | 2 | $174 |
| AbbVie | 1 | $101 |
| Valencia Technologies Corporation | 1 | $62 |
| Caldera Medical, Inc | 1 | $53 |
| Applied Medical Resources Corporation | 1 | $48 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Solyx SIS System$142
- INTERSTIM$108
- Advantage System$103
- BOTOX$101
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Iowato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 61 | $39,843 |
| Estradiol | 140 | $9,881 |
| GemtesaVibegron | 15 | $8,872 |
| Trospium Chloride | 49 | $2,667 |
| Solifenacin Succinate | 18 | $548 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 30 | $432 |
| Cephalexin | 66 | $282 |
| Amitriptyline Hcl | 12 | $204 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Iowa City
- Joseph KowalskiIowa City$2K
- James MasonIowa City$1K
- Catherine BradleyIowa City$842
- Leanne BrechtelIowa City$392
- Rene GenadryIowa City$116
- Michael WoodsShenandoah$18K
- Stephen FeltzDes Moines$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.